ACONW
Aclarion, Inc.
NASDAQ · Healthcare · Medical - Healthcare Information Services · US
$0.03
−35.50%Aug 20, 2026, 11:00 UTC
Aclarion announced the University of Arizona College of Medicine – Phoenix as a new clinical site in its CLARITY trial, bringing the total to ten actively enrolling sites.
Source:Aug 12, 2026, 11:00 UTC
Aclarion, Inc. announced that the United States Patent and Trademark Office issued a Notice of Allowance for its patent application titled 'Multi-Voxel Prescription for Lumbar Disc Evaluation', extending its IP protection to over 65 issued and pending patents worldwide.
Source:Aug 6, 2026, 17:01 UTC
Aclarion, Inc. reported a Q2 2026 loss of $1.12 per share, missing the Zacks Consensus Estimate of a loss of $1.05.
Source:Aug 4, 2026, 11:00 UTC
Aclarion announced that its Nociscan platform is now available at Goodman Campbell Brain & Spine at Ascension St. Vincent, the first site in Indiana to offer the technology.
Source:Jul 7, 2026, 11:00 UTC
Aclarion announced Texas Spine Care Center as a new clinical site for its CLARITY trial of the Nociscan technology.
Source:Jun 9, 2026, 11:00 UTC
Aclarion partnered with PRIA Healthcare to advance reimbursement and commercial adoption of its AI-powered Nociscan platform.
Source:Jun 8, 2026, 11:05 UTC
Aclarion's Board of Directors rejected Echo Lake Capital's unsolicited acquisition proposal.
Source:Jun 3, 2026, 10:00 UTC
Aclarion established an agreement with the Institute of Neuro Innovation to support Nociscan growth and real-world evidence generation.
Source: